SCHEMBL6765355

SCHEMBL6765355

OC[C@H]1O[C@@H](n2cnc3c(-c4cccc(F)c4)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 5/20 0.66
DNPH1 O43598 4/20 0.61
DPP4 P27487 1/20 0.60
MEN1 O00255 1/20 0.60
SLC28A1 O00337 1/20 0.60
MAP3K7 O43318 1/20 0.60
SLC28A2 O43868 1/20 0.60
GAPDH P04406 1/20 0.60
ADORA3 P0DMS8 1/20 0.60
MAPK1 P28482 1/20 0.60
ADORA2A P29274 1/20 0.60
ADORA2B P29275 1/20 0.60
ADORA1 P30542 1/20 0.60
STAT6 P42226 1/20 0.60
PI4KA P42356 1/20 0.60
KMT2A Q03164 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
PI4K2B Q8TCG2 1/20 0.60
DOT1L Q8TEK3 1/20 0.60
PI4K2A Q9BTU6 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6760523 0.91 DNPH1 (0.73) SLC29A1DNPH1ADORA3MAPK1STAT6
SCHEMBL6758917 0.89 SLC29A1 (0.67) SLC29A1DNPH1DPP4MEN1SLC28A1
SCHEMBL6763303 0.88 SLC29A1 (0.68) SLC29A1DNPH1DPP4MEN1SLC28A1
SCHEMBL6423141 0.88 DNPH1 (0.71) SLC29A1DNPH1DPP4MEN1SLC28A1
SCHEMBL6758946 0.88 DNPH1 (0.71) SLC29A1DNPH1DPP4MEN1SLC28A1
SCHEMBL6760662 0.86 DNPH1 (0.69) SLC29A1DNPH1DPP4ADORA3MAPK1
SCHEMBL6760682 0.86 ADK (0.63) SLC29A1DNPH1DPP4MEN1SLC28A1
SCHEMBL6761689 0.86 DNPH1 (0.66) SLC29A1DNPH1ADORA3ADORA2AADORA1
SCHEMBL7030062 0.85 SLC29A1 (0.58) SLC29A1DNPH1ADORA3ADORA2AADORA1
SCHEMBL6765347 0.85 DNPH1 (0.59) SLC29A1DNPH1DPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 US claimed
CN-1466591-A Nucleoside derivatives - 2004-01-07 CN claimed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 US claimed
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 US disclosed
CN-1466591-A Nucleoside derivatives - 2004-01-07 CN disclosed
WO-2002018404-A9 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C HOFFMANN LA ROCHE (CH) 2003-10-02 WO disclosed
EP-1315736-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2003-06-04 EP disclosed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 US disclosed
WO-2002018404-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008841-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 SLC29A1 18/4885DNPH1 1216/4885DPP4 124/4885
US-20040110718-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 SLC29A1 18/4885DNPH1 1216/4885DPP4 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.